AnaptysBio, Inc. - ANAB STOCK NEWS

AnaptysBio (Nasdaq: ANAB) disclosed its Q3 2021 results, highlighting collaboration revenue of $20.9 million, primarily from JEMPERLI approvals. The company anticipates ending 2021 with approximately $600 million in cash post a significant $250 million royalty monetization deal with Sagard Healthcare. Imsidolimab's Phase 3 trials for GPP have commenced, showing promising efficacy with 75% of patients achieving primary endpoints. However, research and development expenses rose to $22.2 million, indicating ongoing investment in clinical programs amidst a net loss of $6.7 million.

AnaptysBio has entered a deal with Sagard Healthcare Royalty Partners, receiving a $250 million upfront payment while granting Sagard an 8% royalty on JEMPERLI sales below $1 billion. Sagard could earn up to $105 million in milestones and will receive royalties of 12-25% on sales above $1 billion. The agreement aims to enhance AnaptysBio's funding for its antibody programs and has capped returns for Sagard at up to 165% by 2027. Analysts predict peak annual sales for JEMPERLI could reach $1.4-$2.8 billion, indicating strong market potential.

AnaptysBio presented promising results from its Phase 2 trial of imsidolimab for generalized pustular psoriasis (GPP) at the 2021 EADV Congress. Six out of eight patients (75%) achieved the primary endpoint at weeks 4 and 16. The treatment led to a 98% reduction in pustules by week 16. Following FDA guidance, a Phase 3 GEMINI-1 trial has been initiated. The company aims to expand imsidolimab's indications to moderate-to-severe acne and hidradenitis suppurativa, with Phase 2 data expected in 2022.

AnaptysBio, a clinical-stage biotechnology company, announced that CEO Hamza Suria will present an overview at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 a.m. ET. The presentation will focus on the company's first-in-class antibody candidates targeting inflammation and immuno-oncology. A replay will be available for 90 days on the investor section of AnaptysBio's website. Their proprietary pipeline includes treatments for various inflammatory diseases and collaborations with GSK and Bristol-Myers Squibb.

AnaptysBio announced the FDA's second approval of GSK's JEMPERLI for advanced solid tumors, expanding treatment options for patients with dMMR cancers. Following the approval, AnaptysBio earned a $20 million milestone payment, adding to $40 million received earlier in 2021. Future milestones include an additional $15 million and $165 million tied to regulatory and commercial achievements, respectively. AnaptysBio is set to receive royalties ranging from 8% to 25% on JEMPERLI's global net sales, with GSK projecting peak sales of £1-2 billion.

AnaptysBio, a clinical-stage biotech firm, reported a net loss of $0.4 million for Q2 2021, down from $21.5 million year-over-year. Collaboration revenue reached $30 million, primarily from JEMPERLI's approval milestones. The FDA has approved JEMPERLI for endometrial cancer, projected to earn AnaptysBio royalties of 8-25% on sales. Looking ahead, the company plans to initiate the GEMINI-1 Phase 3 trial for imsidolimab in Q3 2021 and expects cash reserves to sustain operations through 2024.

AnaptysBio, a clinical-stage biotechnology company, will present at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 1:30 p.m. ET. CEO Hamza Suria will share insights into the company’s innovative antibody product candidates, primarily targeting inflammation and immuno-oncology. Their pipeline includes imsidolimab for dermatological conditions and programs aimed at autoimmune diseases and human inflammatory disorders. The audio presentation will be accessible via the company’s website, with a replay available for 60 days post-event.

AnaptysBio, a clinical-stage biotechnology company, reported its Q1 2021 financial results and pipeline updates. The company anticipates commencing a Phase 3 trial for imsidolimab to treat generalized pustular psoriasis (GPP) following a successful FDA meeting. Approval of JEMPERLI for endometrial cancer resulted in $30 million in milestone payments and ongoing royalties. However, the company reported a net loss of $18.2 million for the quarter, and cash reserves decreased from $411.2 million to $387.4 million. AnaptysBio expects cash burn to be around $100 million in 2021, funding operations into 2024.

AnaptysBio announced that its PD-1 antagonist antibody, JEMPERLI (dostarlimab), has received conditional marketing authorization from the European Commission for treating advanced endometrial cancer. This milestone marks JEMPERLI as the first anti-PD-1 therapy approved for this indication in Europe. AnaptysBio earned a $10 million milestone payment and expects additional payments, including $35 million upon future regulatory milestones and $165 million based on sales achievements. The company will also receive royalties ranging from 8% to 25% on global net sales of JEMPERLI.